1218 related articles for article (PubMed ID: 6355297)
1. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
2. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
3. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
Kochi SK; Johnson RC; Dalmasso AP
J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266
[TBL] [Abstract][Full Text] [Related]
4. Multimeric C9 within C5b-9 deposits in unique locations in the cell wall of Salmonella typhimurium.
Joiner KA; Tartanian AB; Hammer CH; Schweinle JE
J Immunol; 1989 Jun; 142(12):4450-7. PubMed ID: 2656866
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing.
Joiner K; Brown E; Hammer C; Warren K; Frank M
J Immunol; 1983 Feb; 130(2):845-9. PubMed ID: 6848598
[TBL] [Abstract][Full Text] [Related]
6. Role of TraT protein, an anticomplementary protein produced in Escherichia coli by R100 factor, in serum resistance.
Pramoonjago P; Kaneko M; Kinoshita T; Ohtsubo E; Takeda J; Hong KS; Inagi R; Inoue K
J Immunol; 1992 Feb; 148(3):827-36. PubMed ID: 1730875
[TBL] [Abstract][Full Text] [Related]
7. Multimeric C9 within C5b-9 is required for inner membrane damage to Escherichia coli J5 during complement killing.
Bloch EF; Schmetz MA; Foulds J; Hammer CH; Frank MM; Joiner KA
J Immunol; 1987 Feb; 138(3):842-8. PubMed ID: 3100618
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity.
Joiner KA; Warren KA; Tam M; Frank MM
J Immunol; 1985 May; 134(5):3411-9. PubMed ID: 3920319
[TBL] [Abstract][Full Text] [Related]
9. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal but not nonbactericidal C5b-9 is associated with distinctive outer membrane proteins in Neisseria gonorrhoeae.
Joiner KA; Warren KA; Hammer C; Frank MM
J Immunol; 1985 Mar; 134(3):1920-5. PubMed ID: 3918112
[TBL] [Abstract][Full Text] [Related]
11. Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death.
Joiner KA; Hammer CH; Brown EJ; Cole RJ; Frank MM
J Exp Med; 1982 Mar; 155(3):797-808. PubMed ID: 6801179
[TBL] [Abstract][Full Text] [Related]
12. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
13. A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4.
Joiner KA; Goldman R; Schmetz M; Berger M; Hammer CH; Frank MM; Leive L
J Immunol; 1984 Jan; 132(1):369-75. PubMed ID: 6197449
[TBL] [Abstract][Full Text] [Related]
14. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane.
Joiner KA; Hammer CH; Brown EJ; Frank MM
J Exp Med; 1982 Mar; 155(3):809-19. PubMed ID: 6801180
[TBL] [Abstract][Full Text] [Related]
15. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
Tesh VL; Duncan RL; Morrison DC
J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
[TBL] [Abstract][Full Text] [Related]
16. Resistance of Actinobacillus pleuropneumoniae to bactericidal antibody and complement is mediated by capsular polysaccharide and blocking antibody specific for lipopolysaccharide.
Ward CK; Inzana TJ
J Immunol; 1994 Sep; 153(5):2110-21. PubMed ID: 8051416
[TBL] [Abstract][Full Text] [Related]
17. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9.
Puentes SM; Da Silva RP; Sacks DL; Hammer CH; Joiner KA
J Immunol; 1990 Dec; 145(12):4311-6. PubMed ID: 2147941
[TBL] [Abstract][Full Text] [Related]
18. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
Stewart JL; Kolb WP; Sodetz JM
J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane channel-formation by five complement proteins.
Müller-Eberhard HJ
Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
[TBL] [Abstract][Full Text] [Related]
20. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
